Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Film Coated Tablets 14 x 200 mg |
|
||
|
Film Coated Tablets 28 x 200 mg |
|
||
|
Film Coated Tablets 30 x 200 mg |
|
Related information
Dosage
The dosage is determined depending on the patient weight and the type of infection. Please refer to the license holder for further details.
Indications
Invasive aspergillosis,
Fluconazole-resistant serious invasive Candida infections (including C. krusei),
Serious fungal infections caused by scedosporium spp. and fusarium spp.
This medicinal product should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections.
Treatment of candidemia in non-neutropenic patients.
Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
Contra-Indications
Hypersensitivity to voriconazole or to any of the other excipients.
This medicinal product should not be taken with: terfenadine, estemizole, cisapride, pimozide, quinidine, ivabradine, rifabutin, rifampicin, carbamazepine, phenobarbital, ergot derivatives (like ergotamine, dihydroergotamine), sirolimus, efavirenz (at dosage of 400 mg and more given once daily), ritonavir (at dosage of 400 mg and more each time , given twice daily), st. john’s wort, naloxegol, tolvaptan, lurasidone, finerenone, venetoclax.
Please refer to the license holder for further details.
Special Precautions
Please refer to the license holder for further details.
Side Effects
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
Overdose
Please refer to the license holder for further details.
